SBIR-STTR Award

Assay Development of Diagnostic Tests for Hepatitis E.
Award last edited on: 12/23/2014

Sponsored Program
SBIR
Awarding Agency
DOD : Army
Total Award Amount
$597,182
Award Phase
2
Solicitation Topic Code
A90-183
Principal Investigator
Patrice Yarbough

Company Information

Genelabs Technologies Inc (AKA: Gene Labs, Inc.)

505 Penobscot Drive
Redwood City, CA 94063
   (650) 369-9500
   info@genelabs.com
   www.genelabs.com
Location: Multiple
Congr. District: 14
County: San Mateo

Phase I

Contract Number: N/A
Start Date: 8/18/1988    Completed: 00/00/00
Phase I year
1990
Phase I Amount
$50,000
We have previously identified two cDNA clones which encode epitopes specifically recognized by antibodies from human and cynomolgus macaques infected with enterically transmitted non-A, non-B hepatitis virus (HEV). Using the two HEV cDNA clones as probes, we have isolated two additional cDNA clones that contain inserts encoding long open reading frames. Since it is likely that the two newly isolated cDNA clones contain multiple immunogenic sequences, we propose to express both cDNA clones in E. coli or in yeast as fusion proteins. We will then use the purified recombinant proteins to develop a new HEV antibody test based on an enzyme-linked immunosorbent assay (ELISA). We will also develop two confirmatory tests for detecting HEV in human fecal specimens. One confirmatory test will be use of ELISA to capture the HEV viral antigens in clinical samples, and the other test will be based on polymerase chain reactions (PCR) to detect specific nucleotide sequences of HEV.

Phase II

Contract Number: DAMD17-90-C-0092
Start Date: 9/25/1992    Completed: 9/24/1994
Phase II year
1992
Phase II Amount
$547,182
We have previously identified two cDNA clones which encode epitopes specifically recognized by antibodies from human and cynomolgus macaques infected with enterically transmitted non-A, non-B hepatitis virus (HEV). Using the two HEV cDNA clones as probes, we have isolated two additional cDNA clones that contain inserts encoding long open reading frames. Since it is likely that the two newly isolated cDNA clones contain multiple immunogenic sequences, we propose to express both cDNA clones in E. coli or in yeast as fusion proteins. We will then use the purified recombinant proteins to develop a new HEV antibody test based on an enzyme-linked immunosorbent assay (ELISA). We will also develop two confirmatory tests for detecting HEV in human fecal specimens. One confirmatory test will be use of ELISA to capture the HEV viral antigens in clinical samples, and the other test will be based on polymerase chain reactions (PCR) to detect specific nucleotide sequences of HEV.